Rescheduling and DEA Registration: Q&A with Calvin Shannon of BGM and Hannah King, Esq. of Dentons
Wednesday, May 27 at 12:00 p.m. CT from 12:00 – 1:00 PM CT
On April 23, 2026, the Department of Justice (“DOJ”) issued an order placing FDA-approved marijuana products and products containing marijuana subject to a qualifying state-issued license on Schedule III (the “Rescheduling Order”). The Rescheduling Order has left operators facing important decisions around compliance, licensing, taxation, and long-term planning. BGM and Dentons invite you to join us for a timely discussion on cannabis rescheduling, DEA registration requirements, and the evolving regulatory landscape facing medical and adult-use cannabis operators.
Calvin Shannon, Principal at BGM, and Hannah King, Partner at Dentons will discuss the latest developments surrounding federal cannabis rescheduling, what it could mean for medical and adult-use operators.
What You’ll Learn
- The status of federal cannabis rescheduling and what to expect in 2026.
- DEA registration requirements for medical cannabis operators and important filing deadlines.
- How rescheduling may impact IRS Section 280E and cannabis business taxation.
- Key differences between medical and adult-use cannabis treatment under the proposed framework.
- Initial thinking on operational and compliance considerations for dual-license and co-located operators.
- Practical steps cannabis businesses should take now to prepare for potential regulatory changes.
Register for our webinar today to gain practical guidance on navigating cannabis rescheduling, DEA registration, and the evolving federal regulatory framework impacting the cannabis industry.
